BMS 213 (Daklinza 30 mg)
Generic Name: daclatasvir
Pill with imprint BMS 213 is Green, Five-sided and has been identified as Daklinza 30 mg. It is supplied by Bristol-Myers Squibb Company.
Daklinza is used in the treatment of hepatitis c and belongs to the drug class NS5A inhibitors. Daklinza 30 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for BMS 213
Daklinza
- Generic Name:
- daclatasvir
- Imprint:
- BMS 213
- Strength:
- 30 mg
- Color:
- Green
- Shape:
- Five-sided
- Availability:
- Prescription only
- Drug Class:
- NS5A inhibitors
- CSA Schedule:
- Not a controlled drug
- Labeler / Supplier:
- Bristol-Myers Squibb Company
- National Drug Code (NDC):
- 00003-0213
More about Daklinza (daclatasvir)
- Daklinza Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 10 Reviews – Add your own review/rating
- Drug class: NS5A inhibitors
Consumer resources
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2018 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
